Actuate Therapeutics announced FDA clearance of its IND application for an oral formulation of elraglusib, alongside several strategic initiatives...

Actuate Therapeutics announced clinical trial results published in Nature Medicine showing that adding elraglusib to chemotherapy doubled 12-month survival rates in patients with...

Actuate Therapeutics has launched a new strategic research initiative exploring combination therapies with its lead drug, elraglusib. Read more...

Actuate Therapeutics will be presenting at the upcoming Citizens Life Sciences Conference on March 10, with CEO Dan Schmitt....

What does it take to build a true “backbone” cancer therapy? In a recent conversation, Dan Schmitt, CEO of...

Actuate Therapeutics announced the publication of positive Phase II clinical data from a study evaluating elraglusib in combination with platinum...

Actuate Therapeutics has submitted an updated clinical data package to the FDA to support upcoming regulatory discussions with both...

Actuate Therapeutics has launched an exciting new Phase 1b clinical trial in collaboration with Incyte Corporation and the University of...

Actuate Therapeutics, Inc. has achieved extraordinary results in its Phase 1 study of elraglusib in pediatric patients with refractory Ewing...

Actuate Therapeutics, Inc. (ACTU) announced hat the Company will be added to the Russell 3000® Index, with automatic inclusion...